TY  - JOUR
AU  - Del Fresno, Carlos
AU  - García-Arriaza, Juan
AU  - Martínez-Cano, Sarai
AU  - Heras-Murillo, Ignacio
AU  - Jarit-Cabanillas, Aitor
AU  - Amores-Iniesta, Joaquin
AU  - Brandi, Paola
AU  - Dunphy, Gillian
AU  - Suay-Corredera, Carmen
AU  - Pricolo, Maria Rosaria
AU  - Vicente, Natalia
AU  - López-Perrote, Andrés
AU  - Cabezudo, Sofía
AU  - González-Corpas, Ana
AU  - Llorca, Oscar
AU  - Alegre-Cebollada, Jorge
AU  - Garaigorta, Urtzi
AU  - Gastaminza, Pablo
AU  - Esteban, Mariano
AU  - Sancho, David
PY  - 2021
DO  - 10.3389/fimmu.2021.748103
UR  - http://hdl.handle.net/20.500.12105/15094
AB  - COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal...
LA  - eng
PB  - Frontiers Media
KW  - Administration, Mucosal
KW  - Animals
KW  - Antibodies, Viral
KW  - Bacteria
KW  - CD8-Positive T-Lymphocytes
KW  - COVID-19
KW  - COVID-19 Vaccines
KW  - Immunity, Heterologous
KW  - Immunity, Innate
KW  - Immunogenicity, Vaccine
KW  - Immunoglobulin A
KW  - Immunologic Factors
KW  - Mice
KW  - SARS-CoV-2
KW  - Vaccination
TI  - The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
TY  - journal article
ER  -